Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD85d CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD85d CAR-T cells are an experimental adoptive cellular immunotherapy designed to target CD85d (also known as ILT4 or LILRB2), a member of the leukocyte immunoglobulin-like receptor family. CD85d was identified through multi-omic surfaceome mapping as being highly expressed across various acute myeloid leukemia (AML) phenotypes while remaining largely absent from normal hematopoietic stem and progenitor cells (HSPCs) and vital non-hematopoietic tissues. These CAR-T cells are engineered to selectively recognize and eliminate CD85d-positive leukemic blasts, potentially offering a safer alternative to therapies targeting CD33 or CD123, which often cause on-target off-leukemia toxicity due to expression on healthy HSPCs. The therapy is currently in preclinical development at Washington University in Saint Louis.
- Other names
- ILT4 CAR-T cellsILT-4 CAR-T cellsILT 4 CAR-T cellsLILRB2 CAR-T cellsLILRB-2 CAR-T cellsLILRB 2 CAR-T cells
02
Targets
LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)
Beyond the preview
Go deeper on CD85d CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD85d CAR-T cells.